loading
Precedente Chiudi:
$3.70
Aprire:
$3.86
Volume 24 ore:
592.74K
Relative Volume:
0.09
Capitalizzazione di mercato:
$912.72M
Reddito:
$116.33M
Utile/perdita netta:
$-209.25M
Rapporto P/E:
-1.8137
EPS:
-2.12
Flusso di cassa netto:
$-135.49M
1 W Prestazione:
-5.44%
1M Prestazione:
+4.37%
6M Prestazione:
+232.18%
1 anno Prestazione:
+73.64%
Intervallo 1D:
Value
$3.7701
$3.8899
Intervallo di 1 settimana:
Value
$3.66
$4.01
Portata 52W:
Value
$0.6925
$4.13

Esperion Therapeutics Inc Stock (ESPR) Company Profile

Name
Nome
Esperion Therapeutics Inc
Name
Telefono
734-887-3903
Name
Indirizzo
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Name
Dipendente
304
Name
Cinguettio
@esperioninc
Name
Prossima data di guadagno
2025-03-04
Name
Ultimi documenti SEC
Name
ESPR's Discussions on Twitter

Confronta ESPR con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - Specialty & Generic icon
ESPR
Esperion Therapeutics Inc
3.85 877.16M 116.33M -209.25M -135.49M -2.12
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
125.17 55.45B 9.40B 2.65B 2.24B 5.935
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.61 49.25B 29.63B 260.53M 5.51B 0.0788
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.03 45.02B 14.26B 1.98B 2.47B 0.4327
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
30.96 35.81B 16.88B 666.71M 251.19M 0.6132
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
485.41 20.98B 3.08B 1.24B 1.07B 25.61

Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-11-25 Iniziato Piper Sandler Overweight
2024-12-18 Iniziato Goldman Neutral
2024-12-17 Iniziato Cantor Fitzgerald Overweight
2024-06-20 Downgrade BofA Securities Neutral → Underperform
2024-01-03 Downgrade BofA Securities Buy → Neutral
2023-11-20 Ripresa JP Morgan Neutral
2023-08-01 Aggiornamento Northland Capital Under Perform → Market Perform
2023-06-15 Aggiornamento BofA Securities Underperform → Buy
2023-03-16 Downgrade BofA Securities Neutral → Underperform
2023-03-16 Downgrade Northland Capital Market Perform → Under Perform
2023-03-07 Aggiornamento Credit Suisse Underperform → Neutral
2023-02-27 Ripresa BofA Securities Neutral
2023-02-24 Aggiornamento Jefferies Hold → Buy
2023-02-03 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2022-08-03 Downgrade Credit Suisse Neutral → Underperform
2022-05-05 Aggiornamento JP Morgan Underweight → Neutral
2022-03-10 Iniziato H.C. Wainwright Buy
2021-10-19 Downgrade Credit Suisse Outperform → Neutral
2021-10-14 Downgrade Morgan Stanley Equal-Weight → Underweight
2021-05-05 Downgrade Stifel Buy → Hold
2021-04-26 Ripresa Credit Suisse Outperform
2021-03-11 Iniziato Morgan Stanley Equal-Weight
2021-02-12 Downgrade Jefferies Buy → Hold
2021-02-09 Downgrade Goldman Neutral → Sell
2021-01-15 Downgrade BofA Securities Buy → Neutral
2020-11-10 Aggiornamento Credit Suisse Neutral → Outperform
2020-09-29 Ripresa JP Morgan Underweight
2020-08-11 Downgrade Credit Suisse Outperform → Neutral
2020-04-01 Ripresa BofA/Merrill Buy
2020-03-17 Aggiornamento Citigroup Neutral → Buy
2020-02-24 Downgrade Northland Capital Outperform → Market Perform
2020-02-14 Downgrade Citigroup Buy → Neutral
2019-09-16 Aggiornamento Goldman Sell → Neutral
2019-05-29 Downgrade Goldman Neutral → Sell
2019-05-06 Aggiornamento BofA/Merrill Underperform → Neutral
2019-04-26 Aggiornamento Goldman Sell → Neutral
2019-03-13 Aggiornamento JP Morgan Underweight → Neutral
2019-01-07 Reiterato Needham Strong Buy
2018-12-13 Iniziato Goldman Sell
2018-10-29 Aggiornamento Northland Capital Market Perform → Outperform
2018-10-16 Iniziato BTIG Research Buy
2018-08-17 Aggiornamento Citigroup Neutral → Buy
2018-07-11 Downgrade Northland Capital Outperform → Market Perform
2018-05-03 Downgrade JP Morgan Neutral → Underweight
2018-05-02 Downgrade BofA/Merrill Buy → Underperform
Mostra tutto

Esperion Therapeutics Inc Borsa (ESPR) Ultime notizie

pulisher
Dec 31, 2025

Is Esperion Therapeutics Inc a good long term investmentGlobal Trade Effects & Free Rapid Wealth Building - earlytimes.in

Dec 31, 2025
pulisher
Dec 30, 2025

Esperion Therapeutics (NASDAQ:ESPR) Shares Down 4.8%Time to Sell? - MarketBeat

Dec 30, 2025
pulisher
Dec 28, 2025

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Dec 28, 2025
pulisher
Dec 26, 2025

PFE6265887 Bond Coupon Analysis — Rate & Payments - TradingView — Track All Markets

Dec 26, 2025
pulisher
Dec 23, 2025

Esperion Therapeutics (NASDAQ:ESPR) Hits New 52-Week HighTime to Buy? - MarketBeat

Dec 23, 2025
pulisher
Dec 20, 2025

Is Esperion Therapeutics Inc. stock attractive for long term wealth buildingPortfolio Update Summary & Real-Time Volume Triggers - Улправда

Dec 20, 2025
pulisher
Dec 19, 2025

Will Esperion Therapeutics Inc. stock split attract more investorsJuly 2025 Intraday Action & Weekly High Return Stock Forecasts - DonanımHaber

Dec 19, 2025
pulisher
Dec 19, 2025

How Esperion Therapeutics Inc. (0ET) stock compares with top peersQuarterly Portfolio Report & Free Technical Confirmation Trade Alerts - DonanımHaber

Dec 19, 2025
pulisher
Dec 19, 2025

Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes - The Manila Times

Dec 19, 2025
pulisher
Dec 19, 2025

Esperion's Bempedoic Acid Recognized by ACC as Effective LDL-C Lowering Therapy for Patients with PAD and Diabetes - Quiver Quantitative

Dec 19, 2025
pulisher
Dec 19, 2025

Esperion’s Bempedoic Acid Receives Recommendation in 2025 - GlobeNewswire

Dec 19, 2025
pulisher
Dec 19, 2025

Take Profit: Will Esperion Therapeutics Inc. stock maintain momentum in 2025 - DonanımHaber

Dec 19, 2025
pulisher
Dec 19, 2025

New pill cuts serious limb risks for diabetics with artery disease, ACC says - Stock Titan

Dec 19, 2025
pulisher
Dec 19, 2025

Can Esperion Therapeutics Inc. stock hit record highs againJuly 2025 Macro Moves & AI Powered Market Entry Strategies - Улправда

Dec 19, 2025
pulisher
Dec 18, 2025

Esperion Therapeutics Q3 2025 Earnings Preview - MSN

Dec 18, 2025
pulisher
Dec 18, 2025

[Form 4] Esperion Therapeutics, Inc. Insider Trading Activity - Stock Titan

Dec 18, 2025
pulisher
Dec 18, 2025

Esperion Therapeutics (ESPR) CEO files Form 4 for 48,244-share tax sale - Stock Titan

Dec 18, 2025
pulisher
Dec 18, 2025

Esperion Therapeutics (NASDAQ:ESPR) General Counsel Sells $23,917.39 in Stock - MarketBeat

Dec 18, 2025
pulisher
Dec 18, 2025

Esperion Therapeutics (NASDAQ:ESPR) CFO Benjamin Halladay Sells 7,337 Shares - MarketBeat

Dec 18, 2025
pulisher
Dec 18, 2025

Esperion Therapeutics Executives Sell Shares to Satisfy Tax Obligations - TradingView — Track All Markets

Dec 18, 2025
pulisher
Dec 18, 2025

CFO Halladay Surrenders 7,337 Of Esperion Therapeutics Inc [ESPR] - TradingView — Track All Markets

Dec 18, 2025
pulisher
Dec 18, 2025

Esperion Therapeutics (ESPR) CFO reports 7,337-share sale for tax obligations - Stock Titan

Dec 18, 2025
pulisher
Dec 18, 2025

Aug Macro: Will Esperion Therapeutics Inc. (0ET) stock outperform value peers2025 EndofYear Setup & Community Verified Swing Trade Signals - ulpravda.ru

Dec 18, 2025
pulisher
Dec 17, 2025

Officer Looker Files To Sell 6,517 Of Esperion Therapeutics Inc [ESPR] - TradingView — Track All Markets

Dec 17, 2025
pulisher
Dec 17, 2025

PFE6265887 Bond Analysis — Key Metrics - TradingView — Track All Markets

Dec 17, 2025
pulisher
Dec 15, 2025

Investors Purchase High Volume of Call Options on Esperion Therapeutics (NASDAQ:ESPR) - MarketBeat

Dec 15, 2025
pulisher
Dec 12, 2025

Esperion Therapeutics (NASDAQ:ESPR) Sets New 12-Month HighShould You Buy? - MarketBeat

Dec 12, 2025
pulisher
Dec 11, 2025

Esperion’s Stock Surge: Opportunity Knocks?​ - StocksToTrade

Dec 11, 2025
pulisher
Dec 10, 2025

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Sahm

Dec 10, 2025
pulisher
Dec 09, 2025

Why The Narrative Around Esperion Therapeutics Is Shifting After Analyst Upgrades And Trial Results - Yahoo Finance

Dec 09, 2025
pulisher
Dec 09, 2025

Esperion announces inducement grants under Nasdaq Listing Rule - marketscreener.com

Dec 09, 2025
pulisher
Dec 09, 2025

Esperion Grants Stock Options and RSUs to New Chief Commercial Officer and Employees - Quiver Quantitative

Dec 09, 2025
pulisher
Dec 06, 2025

Esperion Therapeutics Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis

Dec 06, 2025
pulisher
Dec 05, 2025

Two Seas Capital LP Raises Holdings in Esperion Therapeutics, Inc. $ESPR - MarketBeat

Dec 05, 2025
pulisher
Dec 05, 2025

Will Esperion Therapeutics Inc. (0ET) stock enhance shareholder valueEarnings Overview Summary & Smart Money Movement Alerts - Newser

Dec 05, 2025
pulisher
Dec 04, 2025

Esperion stock hits fair value target with 77% gain since April 2024 - Investing.com Australia

Dec 04, 2025
pulisher
Dec 03, 2025

Esperion Therapeutics, Inc.Common Stock (Nasdaq:ESPR) Stock Quote - Markets Financial Content

Dec 03, 2025
pulisher
Dec 03, 2025

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Dec 03, 2025
pulisher
Dec 03, 2025

Is Esperion Therapeutics Inc. (0ET) stock a top dividend aristocrat candidateTrend Reversal & Stepwise Trade Execution Plans - Newser

Dec 03, 2025
pulisher
Dec 02, 2025

ESPR SEC FilingsEsperion Therape 10-K, 10-Q, 8-K Forms - Stock Titan

Dec 02, 2025
pulisher
Nov 27, 2025

Esperion Therapeutics (NASDAQ:ESPR) Trading 6% HigherHere's What Happened - MarketBeat

Nov 27, 2025
pulisher
Nov 27, 2025

Esperion a new overweight at Piper Sandler on CV franchise - MSN

Nov 27, 2025
pulisher
Nov 26, 2025

Traders Purchase Large Volume of Call Options on Esperion Therapeutics (NASDAQ:ESPR) - MarketBeat

Nov 26, 2025
pulisher
Nov 26, 2025

Esperion Therapeutics (NASDAQ:ESPR) Coverage Initiated at Piper Sandler - MarketBeat

Nov 26, 2025
pulisher
Nov 26, 2025

Esperion Therapeutics Stock Hits Near 1-Year High As Wall Street Sees Strong Risk-Reward Play On Demand For Cholesterol Drug - Stocktwits

Nov 26, 2025
pulisher
Nov 25, 2025

Esperion Therapeutics: Soaring Momentum Observed - StocksToTrade

Nov 25, 2025
pulisher
Nov 25, 2025

Piper Sandler Initiates Coverage of Esperion Therapeutics (ESPR) with Overweight Recommendation - Nasdaq

Nov 25, 2025
pulisher
Nov 25, 2025

Piper Sandler initiates Esperion Therapeutics stock with Overweight rating By Investing.com - Investing.com South Africa

Nov 25, 2025
pulisher
Nov 25, 2025

Esperion’s Strategic Moves: What It Means? - StocksToTrade

Nov 25, 2025
pulisher
Nov 25, 2025

Esperion Therapeutics Shares Rise After Piper Sandler Initiates Coverage - marketscreener.com

Nov 25, 2025
pulisher
Nov 25, 2025

Esperion Stock Grows Amid Promising Japanese Partnership and Q3 Earnings - timothysykes.com

Nov 25, 2025

Esperion Therapeutics Inc Azioni (ESPR) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
drug_manufacturers_specialty_generic RGC
$21.80
price up icon 6.48%
$22.64
price up icon 0.00%
drug_manufacturers_specialty_generic RDY
$13.86
price down icon 1.32%
$140.52
price down icon 0.54%
$12.36
price down icon 0.28%
$484.95
price down icon 0.54%
Capitalizzazione:     |  Volume (24 ore):